Takeda, Karolinska Institute and Structural Genomics Consortium partner to treat IBD

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Karolinska Institute (Stockholm, Sweden) and Structural Genomics Consortium (SGC) (Headington, U.K.) partnered to discover and validate new intervention points to treat inflammatory bowel disease (IBD). Under the deal, Takeda will fund the research for three years. The translational medicine research team will consist of scientists and clinicians from the three companies, who will develop advanced translational disease models from patient-derived samples. ...